Modelos europeos de telemedicina, como el servicio finlandés Medilux, permiten realizar consultas médicas online mediante un cuestionario clínico, sin acudir a una consulta presencial.

ACC 2022 – POISE-3: Tranexamic Acid, Bleeding and Cardiovascular Events in Non-Cardiac Surgeries

Tranexamic Acid is an antifibrinolytic which has been shown to reduce bleeding in orthopedic patients and cardiac surgery. But evidence for its use in non-cardiac surgery is still limited. 

ACC 2022 - Estudio POISE-3: Ácido tranexámico en pacientes sometidos a cirugía no cardíaca

The aim of this study was to assess whether tranexamic acid reduces the incidence of bleeding events, which include life threatening bleeding, major bleeding, or bleeding into a critical organ (superiority design) and MACE incidence assessment (non-inferiority design) at 30 days, compared against placebo. 

The study randomized 9535 patients, mean age 69, considered at risk of bleeding and cardiovascular events, 76.8% with non-orthopedic surgery. The dose of tranexamic acid was 1gr. both at the start and end of surgery. 

The use of tranexamic acid significantly reduced bleeding incidence (HR 0.76, CI95% 0.67-0.87, p.001), with no evidence of MACE reduction (HR 1.02, CI95% 092-1.14, p: 0.04) and without reaching non-inferiority.

Read also: STEMI: Can We Omit Stenting?

Within the adverse events there was higher risk of seizures (HR 3.35), with no significant differences in serious events (5.5% vs 5.1% p:0.16).

Conclusions 

In patients at risk of bleeding and cardiovascular events set to receive non-cardiac surgery, the use of tranexamic acid significantly reduces bleeding compared against placebo. Despite the low rate of MACE in both groups, non-inferiority was not reached for cardiovascular events. 

Dr. Omar Tupayachi

Dr. Omar Tupayachi.
Member of the editorial board, SOLACI.org

Original Title: Poise-3: Tranexamic Acid in Patients Undergoing Noncardiac Surgery

Reference: Devereaux, P. J., Marcucci, M., Painter, T. W., Conen, D., Lomivorotov, V., Sessler, D. I., Chan, M. T. V., Borges, F. K., Martínez-Zapata, M. J., Wang, C.-Y., Xavier, D., Ofori, S. N., Wang, M. K., Efremov, S., Landoni, G., Kleinlugtenbelt, Y. V., Szczeklik, W., Schmartz, D., Garg, A. X., … POISE-3 Investigators. (2022). Tranexamic acid in patients undergoing noncardiac surgery. The New England Journal of Medicine. https://doi.org/10.1056/NEJMoa2201171


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

EuroPCR 2026 | P2Y12 Inhibitor Monotherapy After Complex PCI in ACS: Results From the NEO-MINDSET COMPLEX Subanalysis

This is a summary of the NEO-MINDSET COMPLEX subanalysis, presented by Dr. Guy Prado at EuroPCR 2026, which evaluated P2Y12 inhibitor monotherapy versus dual...

EuroPCR 2026 | Evolocumab Reduces Cardiovascular Events in Patients With Prior PCI Without Previous Myocardial Infarction: VESALIUS-CV Results

This presentation, delivered by Dr. Brian A. Bergmark and colleagues at EuroPCR 2026, detailed the results of the VESALIUS-CV trial, focusing specifically on the...

EuroPCR 2026 | Is It Safe to Stop Aspirin After One Month in MI Patients Undergoing PCI? TARGET-FIRST Analysis

This is a summary of the post-hoc analysis of the TARGET-FIRST study, presented by Dr. Giuseppe Tarantini at EuroPCR 2026, evaluating early aspirin discontinuation...

EuroPCR 2026 | Could clopidogrel replace aspirin as monotherapy after PCI?

This presentation, delivered during EuroPCR 2026, analyzed the clinical outcomes of clopidogrel monotherapy versus aspirin in patients who remained event-free for 12 months after...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img
Jornadas Guatemala 2026

Recent Articles

EuroPCR 2026 | TAVI in Women: Do Supra-Annular Valves Offer a True Hemodynamic Advantage?

Women represent a particularly challenging population for TAVI, as they often have smaller aortic annuli, greater frailty, and an increased risk of prosthesis-patient mismatch....

EuroPCR 2026 | TAVI or Surgery in Younger Patients? Quality of Life and 3-Year Outcomes from NOTION-2

The expansion of TAVI into younger and lower surgical-risk populations has sparked a new debate: beyond mortality and stroke, which strategy provides better functional...

EuroPCR 2026 | MELA Registry: Myval Showed Lower Aortic Regurgitation Rates in Patients With Large Aortic Annuli

This presentation, delivered by Dr. Salvatore Giordano at EuroPCR 2026, detailed the results of the MELA Registry, a multicenter study comparing the performance of...